HealthQuill Sanofi SA
Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate of worsening episodes in adults with moderate-to-severe asthma, according to a statement.
Drugs Health Pharma

Sanofi’s test drug to treat moderate-to-severe asthma fail to meet goals 

HQ Team April 17, 2025: Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.

Read More
Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the French company will invest 300 million euros for a 16% equity.
Drugs Health Pharma

Sanofi to invest $324m in entity with Orano Med for radioligand therapy

Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the.

Read More
Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's immune system to attack red blood cells, for an upfront $825 million.
Drugs Health Pharma

Recordati buys Sanofi’s drug for autoimmune disease for $825 million

Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's.

Read More
French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply of the medicine.
Drugs Health Pharma

Sanofi to invest $1.4 billion to build new insulin plant in Frankfurt

French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply.

Read More